Injective INJ rises after DC meetings and ETF filings

INJ----

INJ surged more than 23% on Oct. 16 to $9.16, extending a near-70% rebound over the past month as trading activity and leveraged positioning accelerated around a series of U.S. policy meetings, ETF filings and a proposed real-estate tokenization project on the Injective network.

Perpetual futures open interest in INJ rose by roughly $35 million within days of the move, indicating that the rally attracted substantial new derivatives exposure rather than relying solely on spot-market buying. That can amplify gains while prices rise, but it also leaves the token exposed to sharper reversals if leveraged positions begin to close.

The move has lifted INJ far above the roughly $4 area reached earlier this year, though the token remains well below its previous all-time high of $52.60. The earlier decline wiped out more than 85% of INJ’s value from that peak, placing the latest recovery in the context of a market that had already undergone a deep reset.

Washington meetings follow regulatory filings

Injective co-founder and chief executive Eric Chen visited officials in Washington on Oct. 14, including representatives connected to the White House, the U.S. Securities and Exchange Commission and the Commodity Futures Trading Commission, according to Injective.

The meetings came after a sequence of filings and registrations linked to the ecosystem’s attempt to serve regulated financial products.

An Injective-affiliated institutional services entity received SEC registration as a transfer agent on Aug. 19. Under the SEC framework, a transfer agent can maintain ownership records, handle transfers of securities and process corporate actions, including dividend-related administration. The registration applies to the entity, rather than constituting SEC approval of INJ or the Injective blockchain itself.

That distinction is particularly relevant as tokenization projects increasingly try to connect public blockchains with conventional securities administration. Transfer-agent registration could support the operational layer needed for tokenized securities, although it does not by itself authorize a new financial product or guarantee that assets will be issued on-chain.

ETF proposals place INJ in a growing staking debate

Three asset managers — 21Shares, Canary Capital and REX-Osprey — submitted SEC filings in September and early October for exchange-traded funds tied to INJ. The proposed products include both spot exposure and staking features, which would potentially allow a fund to earn network rewards from tokens held in custody.

Canary Capital’s filing proposed staking 90% of the ETF’s INJ allocation on-chain. Such a structure would give the fund exposure to both INJ’s market price and the rewards paid to validators and delegators securing the proof-of-stake network.

The filings do not mean the products have been approved. They do show that INJ has joined a small but expanding group of tokens being considered for fund structures beyond Bitcoin and Ethereum, where staking has become one of the more difficult questions for issuers and regulators. A staking ETF must address custody, liquidity, reward treatment, slashing risk and the ability to meet redemption requests if a portion of the fund’s assets is locked in staking arrangements.

Pentiv outlines $10 billion mortgage-tokenization plan

On Oct. 15, Canadian listed mortgage company Pineapple Financial said it would rebrand as Pentiv and outlined plans to bring a $10 billion real-estate mortgage loan portfolio onto Injective.

The company’s proposal was announced a day after Chen’s Washington meetings and gave the market a tangible use case for Injective’s institutional-finance narrative. If implemented, the plan would involve representing mortgage-related loan assets or records through blockchain infrastructure, potentially allowing faster reconciliation and more programmable settlement processes.

The announcement remains a plan rather than evidence that $10 billion in mortgages has already been tokenized or transferred to the network. Moving regulated loan assets on-chain would require legal, servicing, custody and compliance arrangements alongside the blockchain component. For Injective, the commercial challenge is less about announcing a tokenization target than demonstrating that such assets can be administered within the rules governing mortgage finance.

Governance vote targets predictable trading costs

Injective’s governance proposal IIP-709 was also open for voting this week, with voting scheduled to end the following day. The proposal would move exchange-module actions, including order placement and order cancellation, to a fixed gas-fee model.

Gas fees are transaction charges paid to use a blockchain. A fixed-fee model could give automated market makers, trading firms and other high-frequency users more predictable operating costs than a system where fees fluctuate with network conditions or transaction complexity.

That proposal fits the protocol’s focus on decentralized trading infrastructure. Predictable transaction pricing can matter for applications that submit and cancel large numbers of orders, where small changes in per-transaction costs can determine whether a strategy remains viable.

Revenue and supply figures require careful reading

Injective circulated a comparison showing its protocol-revenue-to-fully-diluted-valuation ratio at 0.95 for 2026 to date, compared with 0.83 for Solana and 0.78 for Arbitrum. Ratios of this type are highly sensitive to the valuation method, period measured and the definition of protocol revenue, making them more useful as a rough comparison than as a standalone valuation verdict.

Token Terminal and LunarCrush data cited in the materials put Injective’s on-chain protocol revenue at about $6 million during the past year and cumulative total fees at about $5.9 million over three years. The same comparison listed Ethereum at $3.8 billion in cumulative fees and Solana at $1.6 billion, illustrating the large gap between Injective’s current network economics and those of the two largest smart-contract ecosystems.

Supply data has also become a point of discussion. Mintscan data shared by market participants showed roughly 123 million INJ in total supply, above the 100 million maximum-supply figure displayed on some market-data websites. Because Injective uses proof-of-stake issuance and has buyback-and-burn mechanisms, token holders need to distinguish between legacy supply labels, circulating supply and the current total recorded on-chain.

The price rally has therefore combined a credible set of institutional and product developments with rapidly expanding futures exposure. The durability of the move will depend less on Washington visits or draft filings alone than on whether proposed funds, tokenized-asset projects and network upgrades progress into operating products that generate sustained on-chain activity.